Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis (2011)

Peer-Reviewed Study · Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E, Anekthananon T, Wanachiwanawin D, Silpasakorn S · May 2011

Suputtamongkol Y et al., 2011-05: Randomized open-label trial in 90 Thai patients with chronic strongyloidiasis showing single-dose oral ivermectin (200 micrograms/kg) cured 96.8% versus 63.3% for seven days of high-dose albendazole.

Parasitological cure rate were 63.3%, 96.8% and 93.1% in albendazole, single dose oral ivermectin, and double doses of oral ivermectin respectively (P = 0.006) in modified intention to treat analysis.

Suputtamongkol Y et al., 2011-05: Randomized open-label trial in 90 Thai patients with chronic strongyloidiasis showing single-dose oral ivermectin (200 micrograms/kg) cured 96.8% versus 63.3% for seven days of high-dose albendazole. Prospective randomized open-label trial, N=90 analysed (30 albendazole 800 mg daily for 7 days; 31 single ivermectin 200 micrograms/kg; 29 two ivermectin doses 2 weeks apart), Thailand, follow-up to 1 year. Comparator: active (albendazole). Funder: not stated in the abstract; declarations state 'The authors have declared that no competing interests exist.' All but one patient had at least one concomitant disease. Quote copied from the PubMed/PMC abstract text. Study type: randomized trial.